证券代码：301206 证券简称：三元生物 公告编号：2024-071 山东三元生物科技股份有限公司 关于回购公司股份的进展公告 1、公司未在下列期间内回购公司股份： （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"） 于 2024 年 7 月 8 日 召开了第四届董事会第二十三次会议，会议审议通过了《关于回购公司股份方案 的议案》，同意公司使用自有资金以集中竞价交易方式回购公司已发行的部分人 民币普通股（A 股），用于后期实施股权激励或员工持股计划。本次回购资金总 额不低于人民币 5,000 万元（含），且不超过人民币 10,000 万元（含），回购价格 不超过 35 元/股（含），回购股份的实施期限自公司董事会审议通过回购股份方 案之日起不超过 12 个月，具体回购股份数量以回购结束时实际回购的股份数量 为准。具体内容详见公司于 2024 年 7 月 ...

一、新增办公地址 | 公司新增办公地址 | | | | --- | --- | --- | | | 山东省滨州市滨北梧桐十路 | 101 号 | | 证券部变更后联系地址 | | | 除上述新增办公地址及变更证券部联系地址外，公司注册地址、原办公地址、 联系电话、传真、电子邮箱等其他投资者联系方式均保持不变。 二、本次变更后公司最新的联系方式 证券代码：301206 证券简称：三元生物 公告编号：2024-070 山东三元生物科技股份有限公司 关于增加办公地址的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 因经营发展需要，山东三元生物科技股份有限公司（以下简称"公司"）新 增加了办公地址，公司证券部等部分部门搬迁至新址办公。现将具体情况公告如 下： 联系地址：山东省滨州市滨北张富路 89 号 山东省滨州市滨北梧桐十路 101 号 邮政编码：256600 电子邮箱：sdsyzq@bzsanyuan.com 联系电话：0543-3529859 公司网址：www.sanyuanbz.com 1 / 2 上述变更自本公告披露之日起正式启用，敬请广大投资者知悉。若 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares, based on a total of 201,865,000 shares[2]. - The company plans to distribute a cash dividend of 1.5 yuan for every 10 shares, totaling 30,279,750 yuan, which represents 100% of the distributable profit[110]. - A cash dividend of RMB 2.50 per 10 shares will be distributed to all shareholders, totaling RMB 50,581,425, with no stock dividends or capital reserve transfers[143]. Financial Performance - The company's operating income for the first half of 2024 was CNY 376,846,697.32, representing a 60.15% increase compared to CNY 235,313,762.07 in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2024 was CNY 51,162,324.04, up 56.32% from CNY 32,729,022.81 in the previous year[12]. - The net cash flow from operating activities reached CNY 22,872,518.72, a significant increase of 9,206.18% compared to CNY 245,777.66 in the same period last year[12]. - Basic earnings per share for the first half of 2024 were CNY 0.26, reflecting a 62.50% increase from CNY 0.16 in the previous year[12]. - The gross profit margin for erythritol was 9.09%, with operating revenue increasing by 51.85% and operating costs increasing by 32.88% compared to the same period last year[72]. - The company reported a net profit of -4.65 million RMB for its wholly-owned subsidiary, with total revenue of 1.09 million RMB during the reporting period[96]. - The total comprehensive income for the first half of 2024 was ¥51,913,757.70, reflecting the company's profitability during this period[179]. Risk Management - The company emphasizes the importance of risk awareness for investors regarding future plans and performance forecasts[2]. - The report includes a section detailing potential risk factors and the company's strategies to address them[2]. - The company faced a temporary anti-dumping tax of 156.7% on erythritol exports to the EU, which could affect its market presence in that region[101]. - The company is facing risks related to potential changes in major customers' operations and purchasing orders due to intensified competition in the erythritol industry[104]. Governance and Compliance - The board of directors has confirmed the accuracy and completeness of the financial report, ensuring no misleading statements or omissions[2]. - The financial report is signed and stamped by the responsible personnel, ensuring its authenticity[4]. - The report outlines the company's governance structure and compliance with regulations[3]. - The company emphasizes legal compliance and social responsibility, ensuring fair treatment of shareholders and maintaining transparent communication[114]. - The company has established a complete supplier management system to protect supplier rights and ensure timely payment[114]. Market Trends and Industry Insights - The global demand for erythritol is projected to reach 238,000 tons in 2024, with a compound annual growth rate (CAGR) of 22% from 2020 to 2024, indicating strong market demand[21]. - The rapid expansion of the sugar-free beverage market in China is a significant driver for the growth of the erythritol industry[21]. - The global trend towards healthier eating, particularly low-calorie and no-calorie foods, provides substantial growth opportunities for erythritol as a preferred sugar substitute[26]. - The company is focused on expanding its market presence and enhancing product offerings in the functional sugar segment[5]. Research and Development - Research and development investment amounted to ¥31,943,684.15, a 48.15% increase, aimed at enhancing competitiveness and market expansion[71]. - The company focuses on R&D for innovative sweeteners, with core patents in fermentation extraction processes, achieving high conversion rates for erythritol production[69]. - The company is actively exploring new sweeteners like allulose and tagatose, aiming to optimize production processes and reduce costs[69]. Production and Operations - The company has achieved a fermentation conversion rate of over 54.5% for its erythritol production, significantly higher than the previous range of 32.9%-47%[62]. - The company has implemented an ERP system integrated with production automation to enhance operational efficiency across procurement, production, storage, and sales[63]. - The company employs a "make-to-order" procurement model for raw materials, ensuring efficient inventory management based on market conditions and production needs[48]. Environmental and Social Responsibility - The company is committed to sustainable development, implementing advanced technologies to reduce energy consumption and carbon emissions in its production processes[40]. - The company has invested in green energy initiatives, including a stable distributed photovoltaic power generation project[113]. - The company emphasizes environmental protection and sustainable development, integrating ecological requirements into business operations to achieve economic, social, and environmental benefits[115]. Shareholder Relations - The actual controller and major shareholders have committed to not transferring or managing their shares for a period of 36 months post-IPO, with specific conditions for share reduction thereafter[116]. - The company has established a performance evaluation system and training programs to enhance employee skills and career advancement opportunities[115]. - The company reported a commitment from major shareholders not to reduce their holdings from October 26, 2023, to April 25, 2024, to maintain investor confidence and market stability[124]. Financial Management - The company will strengthen the management of raised funds to ensure they are used for their intended purposes and achieve expected benefits[121]. - The company has not engaged in any entrusted financial management, derivative investments, or entrusted loans during the reporting period[91][92][93]. - The company reported a decrease in cash and cash equivalents to ¥76,792,909.06 from ¥108,808,330.03, a decline of approximately 29.4%[161]. Future Outlook - The company has plans for market expansion and new product development in the upcoming quarters[184]. - The company aims to enhance its core competitiveness by improving market network construction and increasing technological investments[97]. - The company is implementing strategies to manage raw material price fluctuations, including long-term supply contracts and cost control measures[100].

证券代码：301206 证券简称：三元生物 公告编号：2024-064 山东三元生物科技股份有限公司 关于增加公司经营场所及修订《公司章程》的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开了第五届董事会第二次会议、第五届监事会第二次会议，审议通过了《关 于增加公司经营场所及修订<公司章程>的议案》。现将具体情况公告如下： （一）《山东三元生物科技股份有限公司第五届董事会第二次会议决议》 二、《公司章程》修订情况 鉴于公司拟增加经营场所的相关情况，根据《公司法》《上市公司章程指引》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等法律法规、规范性文件的规定，拟对 《山东三元生物科技股份有限公司章程》（以下简称"公司章程"）中的相关条款 进行修订。具体修订内容如下： | 序号 | | 修订前 | 修订后 | | --- | --- | --- | --- | | 1 | 第五条 | 公司住所：滨州市滨北张富 ...

证券代码：301206 证券简称：三元生物 公告编号：2024-063 山东三元生物科技股份有限公司 关于 2024 年半年度利润分配预案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 山东三元生物科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日召开了第五届董事会第二次会议、第五届监事会第二次会议，会议审议通过了 《关于 2024 年半年度利润分配预案的议案》。现将具体情况公告如下： 一、利润分配预案的基本情况 1 / 3 则，对分配总额进行调整。 二、利润分配预案的合法性、合规性 本次分配预案是在保证公司正常经营和长远发展的前提下，综合考虑公司发 展战略、经营发展需要及广大投资者的利益等因素提出的，上述分配预案的制订， 符合中国证监会《关于进一步落实上市公司现金分红有关事项的通知》《上市公 司监管指引第 3 号——上市公司现金分红》《公司章程》及《未来三年股东回报 规划》等关于利润分配的有关规定以及公司相关承诺，符合公司确定的利润分配 政策、股东长期回报规划，与中国证监会鼓励上市公司现金分红的指导意见相契 合，具备合法性、合规性和 ...

说明：2024 年半年度，公司不存在控股股东及其附属企业非经营性资金占用及其他关联资金占用情况。 法定代表人： 主管会计工作负责人： 会计机构负责人： 山东三元生物科技股份有限公司 2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | 占用方与上 | 上市公司 | 年期 | 2024 年半年度 | 年半年 | 年半年 | 2024 年半 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用 | 市公司 | 核算的会 | 2024 初占用资 | 占用累计发生 | 2024 度占用资金的 | 2024 度偿还累计 | 年度期末 | 占用形成 | 占用性质 | | | 方名称 | 的关联关系 | 计科目 | 金余额 | 金额（不含利 | 利息（如有） | 发生金额 | 占用资金 | 原因 | | | | | | | | 息） | | | 余额 | | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 | - ...

中信建投证券股份有限公司关于对 山东三元生物科技股份有限公司 持续督导的培训报告 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》的相 关规定，中信建投证券股份有限公司（以下简称"保荐人"）于 2024 年 8 月 10 日对山东三元生物科技股份有限公司（以下称"三元生物"）到场的董事、监事、 高级管理人员、中层以上管理人员及上市公司控股股东和实际控制人等相关人员 进行了专门培训，并对未到场的相关人员派发了相关培训资料，督促其认真学习 培训内容，本次培训的具体情况如下： 一、培训时间 中信建投证券股份有限公司 2024 年 8 月 23 日 三、培训内容 保荐人按照《深圳证券交易所上市公司自律监管指引第 13 号—保荐业务》 等法规的要求，对三元生物相关人员进行了专项培训，培训内容主要包括：（1） 董监高责任及义务、（2）股份减持限制、（3）短线交易、（4）内幕交易、（5）窗 口期交易、（6）相关警示案例等。 本次培训期间，接受培训的人员均认真配合保荐人的培训工作，并积极进行 交流沟通，保证了本次培训的顺利开展。通过本次培训，相关人员加深了对董监 高责任及义务、股份减持限制、短线交易、内幕交 ...

中信建投证券股份有限公司关于 山东三元生物科技股份有限公司 2024 年上半年度定期现场检查报告 | 保荐机构名称：中信建投证券股份有限 被保荐公司简称：三元生物 | | | | | --- | --- | --- | --- | | 公司 | | | | | 保荐代表人姓名：陆丹君 联系电话：010-56052340 | | | | | 保荐代表人姓名：陈磊 联系电话：010-56051521 | | | | | 现场检查人员姓名：陆丹君 | | | | | 现场检查对应期间：√上半年 □下半年 | | | | | 现场检查时间：2024 年 8 月 10 日 | | | | | 一、现场检查事项 | | 现场检查意见 | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段（包括但不限于本指引第三十三 条所列）： | | | | | 1.公司章程和公司治理制度是否完备、合规 | √ | | | | 2.公司章程和三会规则是否得到有效执行 | √ | | | | 3.三会会议记录是否完整，时间、地点、出席人员及会议 | √ | | | | 内容等要件是否齐备，会议资料是否保存完整 | | ...

Summary of the Conference Call for Shandong Sanyuan Biotechnology Co., Ltd. Company Overview - Shandong Sanyuan Biotechnology Co., Ltd. was established in 2007, focusing on the fermentation production of erythritol, a high-tech biological enterprise dedicated to the production and research of multifunctional sugars [4][6][10]. Key Industry Insights - The company is facing challenges due to the European Commission's preliminary ruling imposing a 156.7% anti-dumping duty on erythritol products from China, which contributed 81.67% to the company's main business revenue in 2023 [10][11]. - The company reported that the affected products accounted for only 18.79% of its revenue during the investigation period, indicating a limited overall impact [11]. - The global erythritol market is experiencing a supply-demand imbalance, with China's production capacity reaching 380,000 tons/year against a global demand of 173,000 tons in 2022 [14][15]. Financial Performance - In 2023, the company's revenue and net profit decreased by 25.99% and 64.03% year-on-year, respectively, with a net cash flow from operating activities of 57 million yuan, down 31.99% [12]. - The gross margin for erythritol turned negative, dropping from 10.50% in 2022 to -1.11% in 2023, attributed to industry overcapacity and price wars [12][13]. Strategic Responses - The company is implementing cost control measures, including optimizing production processes and increasing automation to reduce energy costs and improve efficiency [12][13]. - To mitigate the impact of the anti-dumping duties, the company is customizing products for EU clients to reduce erythritol content below 90% and is promoting high-quality stevia as an alternative sweetener [11][12]. - The company is expanding its market presence in domestic and emerging markets such as Southeast Asia, India, the Middle East, and South America to reduce reliance on the EU market [11][15]. Product Development and Innovation - The company is focusing on new product development, including the production of allulose and tagatose, with a trial production of 10,000 tons of allulose already underway [17][20]. - The newly developed high-quality stevia has achieved scale production capabilities, with plans to expand to 3,000 tons/year based on market demand [19][20]. - The company is also addressing the cost challenges of tagatose production and aims to lower costs through technological advancements [16][17]. Market Outlook - The company anticipates a recovery in the erythritol market by December 2023, as excess capacity is expected to be gradually eliminated, restoring supply-demand balance [15][16]. - The company is optimistic about the market potential for its new products, particularly high-quality stevia, which is expected to contribute positively to revenue in the future [21]. Conclusion - Shandong Sanyuan Biotechnology Co., Ltd. is navigating significant challenges in the erythritol market due to regulatory changes and competitive pressures. However, through strategic innovation, market diversification, and product development, the company aims to stabilize its performance and enhance its competitive position in the industry [11][15][19].

Group 1: Company Overview and Market Context - The company, Shandong Sanyuan Biological Technology Co., Ltd., is primarily engaged in the production of erythritol, which contributed 81.67% to its main business revenue in 2023 [3] - The company's revenue and net profit for 2023 decreased by 25.99% and 64.03% respectively, with a net cash flow from operating activities of 0.57 billion, down 31.99% year-on-year [4] - The global demand for erythritol in 2022 was 173,000 tons, while China's production capacity reached 380,000 tons per year by May 2023, significantly exceeding global demand [5] Group 2: Impact of Anti-Dumping Measures - The European Commission imposed a temporary anti-dumping tax of 156.7% on erythritol products from China, which has affected the company's sales in the EU market [3] - During the investigation period, the affected products accounted for only 18.79% of the company's revenue, indicating a limited overall impact [4] - The company is actively responding to the anti-dumping measures by customizing products for EU clients and adjusting formulations to reduce erythritol content below 90% to avoid tariffs [4] Group 3: Cost Control and Pricing Strategies - The company is implementing multiple cost control measures to address industry overcapacity and price wars, including optimizing production processes and increasing automation [5] - The gross margin for erythritol has turned positive in the first quarter of this year due to these cost control efforts [5] - The company offers differentiated pricing strategies based on customer needs, providing cost-effective product options to enhance market competitiveness [5] Group 4: Product Development and Market Expansion - The company is focusing on developing new products such as allulose and tagatose, with a production capacity of 10,000 tons of allulose starting trial production [6] - The company has successfully developed a high-quality stevia product with a sweetness level 350 times that of sucrose, which is expected to meet market demand for natural high-intensity sweeteners [6][9] - The company plans to expand the production capacity of high-quality stevia to 3,000 tons per year based on market demand [9] Group 5: Strategic Outlook and Risk Management - The company is closely monitoring market dynamics and is prepared to adapt its strategies to manage cyclical fluctuations in the sweetener industry [6] - It aims to diversify its market presence by exploring opportunities in domestic and emerging markets in Southeast Asia, India, the Middle East, and South America [4] - The company is committed to maintaining financial stability and ensuring sufficient cash flow to support operations during market downturns [7]